AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
Rhea-AI Summary
AEON (NYSE American: AEON) reported constructive FDA feedback from a BPD Type 2a meeting in January 2026 on its analytical similarity strategy for ABP-450, a biosimilar to BOTOX. The Agency found AEON’s analytical methodologies reasonable and acknowledged scientific challenges for the 900 kDa toxin complex. AEON plans to complete the majority of its analytical comparability program in 2026 and intends to request a BPD Type 2b meeting in 2026 to discuss next development steps toward full-label approval under the 351(k) pathway.
Positive
- FDA endorsed analytical development approach at Jan 2026 BPD Type 2a meeting
- Majority of analytical comparability program planned for completion in 2026
- Analytical methodologies deemed reasonable to support program advancement
Negative
- Characterization of the 900 kDa botulinum neurotoxin complex poses scientific challenges
News Market Reaction – AEON
In the Mar 25 session, AEON declined 3.77%, reflecting a moderate negative market reaction. Argus tracked a trough of -15.2% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | CFO appointment | Positive | +7.5% | New CFO with 25+ years finance experience to support ABP-450 milestones. |
| Mar 05 | Scientific abstract | Positive | +2.9% | AAN abstract showing strong primary structure comparability to Botox. |
| Jan 21 | FDA meeting & deals | Positive | -14.0% | BPD Type 2a meeting and shareholder approval of debt/PIPE transactions. |
| Dec 19 | Inducement grants | Neutral | -3.7% | RSU inducement grants for new hires under 2025 Inducement Incentive Plan. |
| Dec 15 | Debt exchange deal | Positive | +19.2% | Daewoong note-for-equity exchange eliminating over 90% of outstanding debt. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive strategic and regulatory updates have often coincided with upward price moves, with one notable divergence on a prior FDA/financing milestone.
Over the last few months, AEON has focused on regulatory progress and capital structure changes around ABP-450. A Daewoong exchange on Dec 15, 2025 that removed over 90% of debt saw a 19.21% gain, while a CFO appointment on Mar 9, 2026 and an AAN abstract on Mar 5, 2026 also drew positive reactions. By contrast, the Jan 21, 2026 BPD Type 2a/financing update was followed by a -13.97% move, highlighting occasional disconnects between constructive news and share performance.
Key Terms
351(k) biosimilar pathway regulatory
biosimilar medical
analytical similarity technical
botulinum neurotoxin medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FDA provided constructive feedback on Company’s analytical similarity strategy under the 351(k) biosimilar pathway
Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with the FDA in 2026 to discuss next steps in the development of ABP-450 as a biosimilar to BOTOX®
IRVINE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced feedback from the U.S. Food and Drug Administration (“FDA” or the “Agency”) following a successful Biosimilar Biological Product Development (BPD) Type 2a meeting.
During the meeting, held in January 2026, the FDA reviewed the Company’s proposed analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback supporting the Company’s planned analytical development approach. The Agency acknowledged the scientific challenges associated with characterizing a 900 kDa botulinum neurotoxin complex, provided constructive feedback on the Company’s proposed development approach and analytical assessment plan, and noted that AEON’s analytical methodologies appeared reasonable to support advancement of the program toward a comprehensive analytical similarity package. The Company believes this feedback provides a clear framework for the remaining analytical components of its biosimilar development program and plans to complete the majority of its analytical comparability program in 2026.
AEON is currently planning to request a BPD Type 2b meeting in 2026 to discuss the next phase of the development program to support approval of ABP-450 as a biosimilar to BOTOX® across all approved therapeutic indications.
“We are highly encouraged by the FDA’s constructive engagement regarding our analytical approach and the data generated to date,” said Rob Bancroft, President and Chief Executive Officer of AEON. “This meeting represents an important regulatory milestone for our ABP-450 biosimilar effort. The Agency’s feedback reinforces our confidence in the strength of our analytical work and our development trajectory as we advance toward full-label therapeutic approval under the 351(k) pathway. We believe this positions AEON to execute efficiently through the most critical phase of biosimilar development—analytical similarity—while maintaining focus on a capital-efficient path toward regulatory approval.”
About the U.S. Biosimilar Pathway
Analytical similarity forms the scientific foundation of the 351(k) pathway and represents the most data-intensive phase of biosimilar development. When analytical comparability across critical quality attributes is robustly demonstrated, the FDA may reduce the scope of required clinical studies under its totality-of-the-evidence framework. Sponsors may also seek extrapolation to additional indications of the reference product when scientifically justified.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company seeking full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Risks and uncertainties include, among others, the finalization and interpretation of FDA meeting minutes, the outcome of future FDA interactions, the scope of any required clinical studies, and the Company’s ability to complete its analytical program as planned, among other risks described in the Company’s filings with the Securities and Exchange Commission.
Contacts
Investor Contact:
Laurence Watts
New Street Investor Relations
+1 619 916 7620
laurence@newstreetir.com
Source: AEON Biopharma
